Pharmacovigilance Programme of India: Recent developments and future perspectives
Authors:
Open Access
- 1 January 2016
- journal article
- review article
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 48 (6) , 624-628
Abstract
Promoting safe use of medicines is a priority of Indian Pharmacopoeia Commission that functions as the National Coordination Center (NCC) for Pharmacovigilance Programme of India (PvPI). One hundred and seventy-nine adverse drug reactions (ADRs) monitoring centers currently report ADRs to NCC. Current India contribution to global safety database reaches 3% and the completeness score is 0.93 out of 1. NCC is taking several measures to enhance patient safety including capacity building for monitoring, surveillance, collaboration with national health programs and other organizations to increase ADR reporting and to ensure that PvPI is a vital knowledge database for Indian regulators. The Central Drugs Standard Control Organization has notified important safety label changes on drugs such as carbamazepine and piperacillin + tazobactam in the year 2015, other drugs are under monitoring for regulatory interventions.Keywords
This publication has 16 references indexed in Scilit:
- Ten-year trends in hospital admissions for adverse drug reactions in England 1999–2009Journal of the Royal Society of Medicine, 2010
- Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-EpisodesPLOS ONE, 2009
- Inappropriate prescribing and adverse drug events in older peopleBMC Geriatrics, 2009
- Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective studyBMC Clinical Pharmacology, 2007
- Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patientsBMJ, 2004
- Adverse drug events and medication errors in AustraliaInternational Journal for Quality in Health Care, 2003
- Adverse drug reactions in a South Indian hospital—their severity and cost involvedPharmacoepidemiology and Drug Safety, 2003
- The evolution of human medicines control from a national to an international perspective.1998
- Frequency and cost of serious adverse drug reactions in a department of general medicineBritish Journal of Clinical Pharmacology, 1998
- The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group.1997